Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)

NCT03331848 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

Parkinson Disease

Interventions

DRUG: Placebo oral capsule
DRUG: PXT002331 - 20mg

Sponsor

Prexton Therapeutics